Five-year outcome in immune-mediated scleritis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Immune-mediated scleritis is a rare condition, and the information on the clinical course and complications is scarce. The aim of this study was to identify prognostic factors, complications, and therapeutic effects in patients with immune-mediated scleritis.
Patients with diagnosis of scleritis and a follow-up time of 5 years were identified. Systemic disease, laboratory investigations, type of scleritis, disease activity, therapy, and complications were recorded. The study design was a retrospective, non-comparative, interventional case series.
Systemic disease was identified in 15 (37 %) patients at presentation and in 18 (45 %) after 5 years. Rheumatoid arthritis (15 %), granulomatosis with polyangiitis (7.5 %), and polychondritis (7.5 %) were the most predominant disorders. Persistent scleritis (>5 years) was associated with systemic disease (66 vs. 6 %; p < 0.05) and positive auto-antibodies (48 vs. 23 %; p = 0.18). Control of ocular inflammation was achieved in 38 of 40 (95 %). Prednisone (14 patients) and/or methotrexate (8) were the predominant drugs to control persistent disease. Complications included interstitial keratitis (2), inflammatory astigmatism (2), corneal melt (3), macular edema (6), and severe systemic disease (5).
The presence of systemic disease and positive auto-antibodies are associated with persistent scleritis. Immunosuppressive agents allow control of scleritis, but may contribute to severe systemic complications.
- Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA (2004) Evaluation of patients with scleritis for systemic disease. Ophthalmology 111:501–506 CrossRef
- Sainz de la Maza M, Foster CS, Jabbur NS (1995) Scleritis associated with systemic vasculitic diseases. Ophthalmology 102:687–692 CrossRef
- Watson PG, Heyreh SS (1976) Scleritis and episcleritis. Br J Ophthalmol 60:163–191 CrossRef
- Bernauer W, Ficker LA, Watson PG, Dart JKG (1995) The management of corneal perforations associated with rheumatoid arthritis. Ophthalmology 102:1325–1337 CrossRef
- Sainz del la Maza, Jabbur NS, Foster CS (1993) An analysis of therapeutic decisions for scleritis. Ophthalmology 100:1372–1376 CrossRef
- Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS (2012) Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology 119:43.50
- Wieringa WG, Sieringa JE, Dam-van Loon NH, Los LI (2013) Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology 120:379–386 CrossRef
- McCluskey PJ, Wakefield D (1996) Scleritis and Episcleritis. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity, 1st edn. Mosby, St. Louis, pp 642–662
- Arellanes-Garcia L, del Carmen Preciado-Delgadillo M, Graza-Leon M (2011) Refractive changes in patients with autoimmune scleritis. J Ophthalmol Inflamm Infect 1:173–175 CrossRef
- Meller D, Böker T (1997) Complications of misdiagnosed and inadequately treated necrotizing scleritis studied by ultrasound biomicroscopy and computerized corneal topography. Int Ophthalmol 21(1):35–37 CrossRef
- Tuft SJ, Watson PG (1991) Progression of scleral disease. Ophthalmology 98:467–471 CrossRef
- Five-year outcome in immune-mediated scleritis
Graefe's Archive for Clinical and Experimental Ophthalmology
Volume 252, Issue 9 , pp 1477-1481
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Immunopressive therapy
- Industry Sectors